Here is the dividend forecast to 2028 for CSL shares

Are investors going to get healthy dividends from this stock?

| More on:
A doctor or medical expert in COVID protection adjusts her glasses, indicating growth or strong share price movement in ASX medical, biotech and health companies

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

CSL Ltd (ASX: CSL) shares have done very well for investors over the long term. The CSL share price has lifted around 300% over the past decade. Is the CSL dividend forecast looking optimistic for the ASX healthcare share? I'm going to look at that in this article.

The company is known for many elements, including its vaccines, blood plasma collection and related products, and more. It's a very large biotechnology business with a market capitalisation of $134.6 billion.

CLS has achieved significant profit growth over the past decade, which has helped fund impressive dividend growth over that period. We're going to look at how far the broker UBS thinks the CSL dividend could rise.

FY24 projection

CSL had a solid start to the 2024 financial year. In the first half of FY24, revenue increased 11% to $8.05 billion and net profit after tax (NPAT) rose 17% to $1.9 billion, while underlying net profit (NPATA) rose by 11%.

For FY24, CSL expects underlying profit to be between $2.9 billion and $3 billion, representing growth of 13% to 17%.

UBS thinks the ASX healthcare share can achieve a dividend per share of US$2.60 in FY24, which would represent an increase of around 10%. In Australian dollar terms, that would be an annual dividend payout of $3.98 for CSL shares, which would represent a dividend yield of 1.5%.

How about FY25?

The ASX healthcare share is expected to see a good increase in profitability over the next few years.

UBS suggests the net profit could grow by 18.5% to $3.6 billion. The broker thinks the dividend might be hiked by another 10% to US$2.86 per share.

And FY26?

Next, the 2026 financial year could see more profit growth for the ASX healthcare share, which could rise 19.6% to US$4.3 billion.

If that impressive profit growth occurs, it could enable a 9.8% increase in the CSL dividend to US$3.14 per share.

Expectations for FY27

The 2027 financial year may see another good result for CSL, with a possible profit rise of 20%. If that happens, the dividend growth could be 10.2% to US$3.46 per share.

Finally, here's the FY28 forecast

It's a long way away, but the current suggestion by UBS is that CSL's profit could grow 10.9% to $5.7 billion in FY28. If CSL achieves that, it would mean the net profit could rise by almost 90% between FY24 to FY28.

CSL's dividend per share in FY28 could reach US$3.80 per share, which would be A$5.82. At the current CSL share price, that would be a dividend yield of 2.1%, which isn't exactly a huge yield, but would represent a good growth rate compared to FY24.  

While it's impossible to know what's going to happen, CSL is giving itself a good chance of growth thanks to the billions of dollars it's investing in research and development to create new products and build new earnings streams.

Motley Fool contributor Tristan Harrison has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended CSL. The Motley Fool Australia has recommended CSL. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

A women has her eyes checked at the optometrist.
Healthcare Shares

Is Medibank stock a good buy?

Can this company provide healthy returns?

Read more »

A woman jumps for joy with a rocket drawn on the wall behind her.
Healthcare Shares

Guess which ASX healthcare stock is jumping 7% on US FDA approval news

This share is giving its shareholders an early Christmas present.

Read more »

A senior pharmacist talks to a customer at the counter in a shop
Healthcare Shares

Is it too late to buy Sigma shares to cash in on the Chemist Warehouse deal?

Can investors still make healthy returns with this stock?

Read more »

Shot of a scientist using a computer while conducting research in a laboratory.
Healthcare Shares

Why the Mesoblast share price is diving 18% after an FDA win

Investors are sending the Mesoblast share price tumbling on Friday. But why?

Read more »

A happy doctor in a white coat dancing due to his excitement over the EBOS acquisition
Healthcare Shares

Mesoblast share price rockets 30% on big US FDA news

Big news is giving this biotech a huge lift on Thursday.

Read more »

Two scientists in a Rhythm Biosciences lab cheer while looking at results on a computer.
Healthcare Shares

Guess which ASX healthcare stock is jumping 12% on Wednesday

This shares is rocketing this morning. But why? Let's find out.

Read more »

Man holding out Australian dollar notes, symbolising dividends.
Healthcare Shares

Here is the dividend forecast to 2029 for CSL shares

Can this blue-chip giant provide healthy dividend income?

Read more »

a doctor in a white coat makes a heart shape with his hands and holds it over his chest where his heart is placed.
Healthcare Shares

The best ASX 200 healthcare stocks to buy in 2025

These shares could give your portfolio a healthy boost next year according to Bell Potter.

Read more »